



28th May, 2015

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza", C-1, Block G,
Bandra-Kurla Complex,
Bandra (E), Mumbai – 400 051.

Sub.: Outcome of Board Meeting
Ref. : (i) Symbol – DISHMAN
(ii) Series – EQ

Dear Sir,

1. The Board has deferred the Agenda relating to approval of the Audited financial statements for the year ended 31st March, 2015 in view of disagreement with the statutory auditors with regard to reporting in the consolidated financial statements regarding accounting of employee pension benefits by the Swiss subsidiary CARBOGEN AMCIS, which is covering this liability by participating in an employee retirement benefit plan of a large and well respected insurance company. As per Swiss GAAP, the said subsidiary has no liability for the same. However, the accounting treatment as per Indian GAAP is creating a technical anomaly and being material, the Board has felt it prudent to defer this Agenda item so that the matter can be appropriately addressed.

2. Consequently the agenda items relating to recommendation of dividend and other items related to audited financial result have also been deferred.

3. Key Highlights of Unaudited Financial results for the quarter/year ended appended herewith for the benefits of stakeholders.

Kindly take the same on your record and oblige.

Thanking you.

Yours faithfully,
For, Dishman Pharmaceuticals and Chemicals Limited

Tushar D. Shah
Company Secretary

Dishman Pharmaceuticals and Chemicals Limited

Registered Office: Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad – 380 009 India.

Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198

Email: dishman@dishmangroup.com Web: www.dishmangroup.com

Government Recognised Export House

CIN NO L24230GJ1983PLC006329

CONSOLIDATED											
PARTICULARS		For The Quarter ended 31-03-2015	For The Preceding Quarter ended 31-12-2014	For The Corresponding Quarter ended 31-03-2014	For Year ended 31-03-2015	For Corresponding Year ended 31-03-2014	For The Quarter ended 31-03-2015	For The Preceding Quarter ended 31-12-2014	For The Corresponding Quarter ended 31-03-2014	For Year ended 31-03-2015	For Corresponding Year ended 31-03-2014
Sl. No.											
1	Income From Operations	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	a) Net sales/income from operations (Net of excise duty)	16,005.88	11,835.94	15,680.50	47,745.18	47,199.27	42,062.31	38,594.34	40,065.20	1,56,034.98	1,37,323.75
	b) Other Operating Income	40.62	27.63	55.35	124.13	128.84	304.19	383.80	876.57	1,483.78	1,208.25
	Total Income from operations (net)	16,046.50	11,863.57	15,745.86	47,869.31	47,328.11	42,366.50	38,978.14	40,941.77	1,57,518.76	1,38,532.00
2	Expenses										
	a) Cost of material consumed	4,807.56	5,448.59	4,918.61	19,622.82	17,897.21	12,500.12	14,213.01	11,710.86	55,172.34	39,594.34
	b) Purchase of stock-in-trade	2,323.79	0.89	2,595.83	347.41	516.09	2,423.79	0.89	347.41	2,596.93	516.09
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,517.10	(1,246.46)	271.30	(2,269.23)	(846.67)	3,504.01	(1,469.03)	(127.08)	(4,259.00)	(2,776.74)
	d) Power & Fuel	510.39	988.98	651.85	3,166.98	2,608.77	8,427.37	41,233.36	11,412.17	42,320.84	41,233.36
	e) Employee benefits expense	1,443.66	1,519.52	1,562.82	5,887.92	5,637.83	8,427.37	11,350.47	11,412.17	10,565.23	10,565.23
	f) Depreciation and amortisation expense	1,059.86	1,137.50	993.89	4,413.24	4,413.47	7,067.30	2,946.26	2,911.58	15,071.11	2,946.26
	g) Other Expenditure	901.40	985.04	976.99	3,948.95	3,593.82	7,984.51	7,481.30	8,828.43	30,318.74	26,730.33
	Total expenses	12,664.16	8,874.46	9,818.96	37,357.21	34,120.52	41,867.10	34,122.89	35,083.37	1,41,210.96	1,16,154.81
3	Profit / (Loss) from Operations before Other Income, finance costs and exceptional items (1-2)	3,382.34	3,009.11	5,926.90	10,512.10	13,207.59	493.40	4,855.25	5,858.40	16,307.80	22,377.39
4	Other Income	3,101.74	599.67	4,571.84	6,699.77	5,597.56	7,271.16	779.15	1,694.75	8,599.89	2,464.49
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	6,484.08	3,608.78	10,498.74	17,211.87	18,805.15	7,770.56	5,634.40	7,543.15	24,908.69	24,841.88
6	Finance costs	1,500.58	2,211.60	1,218.46	6,813.28	6,927.51	2,498.83	2,568.25	2,459.60	8,970.84	9,205.37
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	4,983.50	1,437.18	9,280.28	10,398.59	11,883.64	5,271.73	3,066.14	5,083.55	15,935.85	15,636.51
8	Exceptional Items										
9	Profit/(Loss) from Ordinary Activities before tax (7+8)	4,983.50	1,437.18	9,280.28	10,398.59	11,883.64	5,271.73	3,066.14	5,043.55	15,935.85	15,636.51
10	Tax expense	2,772.11	632.73	2,300.50	4,534.75	3,204.98	1,396.52	692.73	2,787.64	3,943.81	4,713.00
11	Net Profit/(Loss) from Ordinary Activities after tax (9-10)	2,211.39	804.45	6,979.78	5,863.84	8,678.66	3,875.21	2,403.41	2,255.91	11,992.04	10,923.51
12	Extraordinary Items (net of tax expense)	-	-	-	5,863.84	8,678.66	3,875.21	2,403.41	2,255.91	11,992.04	10,923.51
13	Net Profit/(Loss) for the period (11+12)	2,211.39	804.45	6,979.78	5,863.84	8,678.66	3,875.21	2,403.41	2,255.91	11,992.04	10,923.51
14	Income from Associates	-	-	-	-	-	1.35	(0.02)	2.69	4.86	3.71
15	Minority Interest	-	-	-	-	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	2,211.39	804.45	6,979.78	5,863.84	8,678.66	3,876.56	2,403.39	2,258.60	11,996.90	10,927.22



